Molecular Partners
MOLN
7 hedge funds and large institutions have $13.9M invested in Molecular Partners in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.
40% more funds holding
Funds holding: 5 → 7 (+2)
0.21% less ownership
Funds ownership: 9.58% → 9.37% (-0.21%)
99% less capital inflows, than outflows
Capital inflows: $248 | Capital outflows: $20.4K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
+$186 |
| 2 |
JP Morgan Chase
New York
|
+$62 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$529 |
MOLN Hedge Fund Activity: Q3 2026 in Review
7 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q3 2026, worth a combined $13.9M — up 0.81% from $13.8M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new MOLN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $186. The largest seller was Citadel Advisors, cutting an estimated $19.8K.
- 7 institutional investors held Molecular Partners (MOLN) as of Q3 2026, up from 5 in Q2 2026.
- Funds reported $13.9M of Molecular Partners stock for Q3 2026, up 0.81% quarter-over-quarter.
- 2 funds opened new Molecular Partners positions in Q3 2026 and 0 closed out, a net change of +2 holders.
- The largest Molecular Partners buyer in Q3 2026 was Tower Research Capital (TRC), an estimated $186 added.
- The largest Molecular Partners seller in Q3 2026 was Citadel Advisors, an estimated $19.8K sold.
Based on aggregated 13F filings for Q3 2026.